MedImmune, a biotechnology company headquartered in Gaithersburg, MD, is focused on development of vaccines and antibodies designed to impact patient health.

The company's leading biologics are:

Synagis (palivizumab). Synagis is the first monoclonal antibody successfully developed to prevent serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in high-risk pediatric patients.

FluMist (intranasal influenza virus vaccine). FluMist, delivered as a nasal mist, is a live virus vaccine that uses a modified attenuated (weakened) form of the influenza virus to stimulate a protective immune response against the influenza A and B viruses.

*Information above taken from materials provided by MedImmune.